| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1036-100 | Anti-human B7-H3, 2C1 antibody | 100µg | $185 | Order |
| A1036-200 | Anti-human B7-H3, 2C1 antibody | 200µg | $325 | Order |
| Catalog Number | A1036 |
|---|---|
| Product Name | Anti-human B7-H3 antibody |
| Source | Mouse hybridoma |
| Clone | 2C1 |
| Species Reactivity | Human and cynomolgus B7-H3, bind weakly to mouse B7-H3 |
| Isotype | Mouse IgG1 |
| Purity | >95% |
| Formulation | 1x PBS, pH7.0. Sterile |
| Stability & Storage | 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw |
| Protein Aggregation | Not obvious on SDS-PAGE |
| Application | Flow cytometry, ELISA, cell-based assay |
| Product Datasheet: | Download PDF |
B7-H3, also known as CD276, is a cell surface protein that belongs to the B7 family of immune regulatory molecules. B7-H3 has two isoforms determined by its extracellular domain. In mice, the extracellular domain consists of a single pair of immunoglobulin variable (IgV)-like and immunoglobulin constant (IgC)-like domains, whereas in humans it consists of one pair (2Ig-B7-H3) or two identical pairs (4Ig-B7-H3) due to exon duplication. B7-H3 mRNA is expressed in most normal tissues. Flow cytometric analysis demonstrated inducible expression of B7H3 on monocytes, dendritic cells, and T cells after stimulation with selected cytokines and mitogens. B7-H3 protein is expressed at high frequency on many different cancer types (60% of all cancers).B7-H3 has both costimulatory and coinhibitory properties that can affect the proliferation of CD4+ and CD8+ T cells, production of cytokines, and activity of T cells and NK cells depending on the microenvironment. B7-H3 also exhibits nonimmunological pro-tumorigenic functions such as migration and invasion, apoptosis, cell viability and chemoresistance.
Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:269-274. 2001.
Zhou WT, Jin WL. B7-H3/CD276: An Emerging Cancer Immunotherapy. Front Immunol. 12:701006. 2021.
Picarda E, Ohaegbulam KC, Zang X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res. 22:3425-3431. 2016.
